MY ACCOUNT | NEWSLETTER |

PetSmart Charities, Red Cross partner to tackle humanitarian missions


PetSmart Charities and the American Red Cross recently announced a partnership years in the making that will support pets as essential family members during times of disaster. More specifically, PetSmart Charities will support Red Cross Disaster Relief through the Annual Disaster Giving Program with a three-year pledge of more than $2 million, according to a news release.   

The innovative collaboration will ensure the Red Cross is prepared to meet the needs of people and their pets affected by disasters big and small across the U.S. This partnership is the first of its kind between two foundational nonprofits — the leading funder of animal welfare and the largest disaster relief organization in the country.  

Aimee Gilbreath, president of PetSmart Charities, said in the release that nearly 90% of pet owners say their pets are members of the family. “This becomes especially clear during times of crises,” she said in the release.  

“We know this critical funding will help ensure the organization is prepared to meet the growing needs of both people and pets affected by disasters. Pets play an important role in the emotional wellness of the people they love, and we want to ensure there are resources in place to provide for their stability, too.”  

Through the partnership, the organizations will create initiatives that include making sure pet tracking is included in RC Cares, the client management systems for the Red Cross, allowing staff and volunteers to provide services to all family members virtually or with “boots on the ground" in disaster situations. The organizations will also create pet-centric training and sheltering models with the Red Cross for its disaster response staff and volunteers.

Like0
Dislike0
  • Please enter a comment


Name *
Email address *
Comment *


* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.


I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies



More news

Feline injection site sarcomas

Like0
Dislike0

C-reactive protein concentrations in canine acute pancreatitis

Like0
Dislike0

A retrospective clinical investigation of the safety and adverse effects of pantoprazole in hospitalized ruminants

Like0
Dislike0

Dr. Marjorie Bercier Publishes Study on Novel Diagnostic Approach for Prevalent Elephant Virus

Like0
Dislike0

FDA Approves BRAVECTO® QUANTUM (Fluralaner for Extended-Release Injectable Suspension) from Merck Animal Health

Like0
Dislike0

Newsletter

 
 

News of interest

EVENTS

Copyright © 2025 - All Rights Reserved
ISSN 2768-198X

Top